Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.50 |
| ▸ | MDM4 | O15151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401455 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A | |
| SCHEMBL30477937 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A | |
| SCHEMBL29398070 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A | |
| SCHEMBL30252212 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A | |
| SCHEMBL119402 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A | |
| SCHEMBL2366569 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A | |
| SCHEMBL2366563 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A | |
| SCHEMBL1738651 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A | |
| SCHEMBL31575313 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A | |
| SCHEMBL12055781 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0357750-B1 | URETHANE-PROTECTED AMINO ACID-N-CARBOXYANHYDRIDES | BIORESEARCH INC (US) | 1994-07-13 | — | — | EP | claimed |
| US-12012468-B2 | Cyclic polypeptides for PCSK9 inhibition | MERCK SHARP & DOHME LLC (US) | 2024-06-18 | — | — | US | disclosed |
| CN-118047737-A | Preparation method of amide compound | 湖北师范大学 | 2024-05-17 | — | — | CN | disclosed |
| US-20240156969-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEAGEN INC (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240148664-A1 | LIPID AND COMPOSITION | SOGO PHARMACEUTICAL CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4321524-A1 | LIPID AND COMPOSITION | Sogo Pharmaceutical Co., Ltd. (JP) | 2024-02-14 | — | — | EP | disclosed |
| CN-117500819-A | Lipid and composition | 相互药工株式会社 | 2024-02-02 | — | — | CN | disclosed |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230303625-A1 | CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION | RA PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| EP-3810129-B1 | PCSK9 ANTAGONIST BICYCLO-COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-6194195-B1 | PURE CULTURE; FOR PRODUCTION OF HYPOTENSIVE AGENTS AND THERAPIES FOR ASTHMA, CEREBRAL APOPLEXY, ANGINA PECTORIS, ACUTE RENAL FAILURE, CARDIAC INFARCTION, AND CEREBRAL VASOSPASM | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-02-27 | — | — | US | disclosed |
| EP-0963999-A1 | E2F ACTIVITY INHIBITORY COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1999-12-15 | — | — | EP | disclosed |
| EP-0922710-A1 | PEPTIDES PROMOTING THE ACTIVATION OF LATENT TGF-$g(b) AND METHOD FOR SCREENING TGF-$g(b) ACTIVITY REGULATORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1999-06-16 | — | — | EP | disclosed |
| EP-0770623-A1 | NOVEL CALCITONIN DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-05-02 | — | — | EP | disclosed |
| EP-0679658-A1 | ENDOTHELIN-ANTAGONIZING PEPTIDE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1995-11-02 | — | — | EP | disclosed |
| EP-0672680-A1 | NOVEL PEPTIDE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1995-09-20 | — | — | EP | disclosed |
| EP-0357750-B1 | URETHANE-PROTECTED AMINO ACID-N-CARBOXYANHYDRIDES | BIORESEARCH INC (US) | 1994-07-13 | — | — | EP | disclosed |
| EP-0603399-A1 | ENDOTHELIN-ANTAGONIZING PEPTIDE | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1994-06-29 | — | — | EP | disclosed |
| US-5028693-A | Preparation of polypeptides, fewer by-products | BIORESEARCH, INC. (US) | 1991-07-02 | — | — | US | disclosed |
| US-4946942-A | Urethane-protected amino acid-N-carboxyanhydrides | BIORESEARCH, INC. (US) | 1990-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148664-A1 | LIPID AND COMPOSITION | PLIN3, PLIN1, FABP1 | CASP3 2725/4885MDM4 2121/4885TP53 1707/4885 |
| US-20230303625-A1 | CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION | PCSK9, LDLR, PCSK7 | CASP3 2160/4885MDM4 4394/4885TP53 3599/4885 |
| US-20240156969-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | LCK, UACA, TEKT1 | CASP3 1499/4885MDM4 4684/4885TP53 1916/4885 |
| US-12012468-B2 | Cyclic polypeptides for PCSK9 inhibition | PCSK9, LDLR, PCSK7 | CASP3 2160/4885MDM4 4394/4885TP53 3599/4885 |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | LCK, UACA, TEKT1 | CASP3 1499/4885MDM4 4684/4885TP53 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.